Last €3.34 EUR
Change Today +0.169 / 5.34%
Volume 0.0
NVV On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 2:16 AM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

novavax inc (NVV) Snapshot

Open
€3.33
Previous Close
€3.17
Day High
€3.34
Day Low
€3.33
52 Week High
02/28/14 - €5.20
52 Week Low
08/12/13 - €1.72
Market Cap
794.2M
Average Volume 10 Days
943.0
EPS TTM
--
Shares Outstanding
238.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NOVAVAX INC (NVV)

novavax inc (NVV) Related Bloomberg News

View More Bloomberg News

novavax inc (NVV) Related Businessweek News

No Related Businessweek News Found

novavax inc (NVV) Details

Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing recombinant protein nanoparticle vaccines and adjuvants. The company’s vaccine technology platform is based on proprietary recombinant nanoparticle vaccine technology that includes virus-like particles vaccines and protein nanoparticle vaccines. Its vaccine candidates target seasonal influenza, pandemic influenza, and respiratory syncytial virus. The company also develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. has a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Gaithersburg, Maryland.

213 Employees
Last Reported Date: 03/12/14
Founded in 1987

novavax inc (NVV) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $448.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $156.3K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $371.9K
Senior Vice President of Global Manufacturing...
Total Annual Compensation: $284.5K
Compensation as of Fiscal Year 2013.

novavax inc (NVV) Key Developments

Novavax, Inc. Announces Management Promotions Within its Management Team

Novavax, Inc. announced a number of promotions within its management team. John A. Herrmann III, J.D. has been named Senior Vice President, General Counsel and Corporate Secretary. Mr. Herrmann joined the company in March 2010 and is responsible for managing all of Novavax' legal affairs, including its patent portfolio, transactional and contractual matters, public securities filings, and attending to all the duties of Corporate Secretary. Mr. Herrmann also works with the company's senior management team to define and develop corporate policies and procedures. Prior to joining Novavax, Mr. Herrmann served as General Counsel at Ore Pharmaceuticals and Deputy General Counsel at Gene Logic before it became Ore Pharmaceuticals. Denise Courbron, M.S., PMP has been named Vice President, Global Program Management to lead Novavax' program management efforts covering all vaccine development programs. Ms. Courbron joined Novavax in June 2010 as Executive Director, Global Program Management and was instrumental in Novavax' being awarded its $179 million influenza development contract with HHS BARDA in February 2011. Prior to joining Novavax, Ms. Courbron held positions of increasing responsibility in a number of companies in the vaccines industry, including PharmAthene, Intercell USA, Iomai Corporation, PPD, Baxter BioScience, GloboMax (ICON), and North American Vaccine.

Novavax, Inc. Announces Board of Directors Changes

Novavax, Inc. announced that on June 12, 2014, John O. Marsh, Jr., resigned as a member of its Board of Directors. The Board of Directors has named Mr. Marsh Director Emeritus. Mr. Marsh served in the U.S. Army during World War II and continued with the Army Reserve and Army National Guard into the 1960s. A graduate of Washington and Lee University Law School, Mr. Marsh began practicing law in 1952 in a variety of state and municipal roles. From 1963 until 1971 he served as a member of the U.S. House of Representatives. In 1973, he was appointed Assistant Secretary of Defense, and in January 1974, became the National Security Advisor for then Vice President Gerald Ford. He subsequently became President Ford's cabinet-ranking Counsellor to the President. In 1981, Mr. Marsh was appointed Secretary of the Army by President Ronald Reagan where he served until 1989. Mr. Marsh has been awarded the Department of Defense Distinguished Public Service Award on six occasions and was awarded the Presidential Citizens Medal from President Reagan.

Novavax, Inc. Appoints Ernst & Young LLP as Auditors

Novavax, Inc. announced that its stockholders ratified the appointment of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVV:GR €3.34 EUR +0.169

NVV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dynavax Technologies Corp $1.42 USD +0.01
Inovio Pharmaceuticals Inc $13.10 USD 0.00
Peregrine Pharmaceuticals Inc $1.58 USD +0.0099
Progenics Pharmaceuticals Inc $5.12 USD +0.13
ZIOPHARM Oncology Inc $3.34 USD +0.02
View Industry Companies
 

Industry Analysis

NVV

Industry Average

Valuation NVV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 38.6x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 39.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVAVAX INC, please visit www.novavax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.